Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curt D. Furberg

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
Journal of Clinical Lipidology|December 16, 2014
The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular diseasePeter P Toth, George Thanassoulis, Ken Williams, et al.
American Heart Journal|August 11, 2012
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studiesDavid Madigan, Daniel W Sigelman, James W Mayer, et al.
Plos One|November 11, 2011
Suicidal behavior and depression in smoking cessation treatmentsThomas J Moore, Curt D Furberg, Joseph Glenmullen, et al.
The American Journal of Cardiology|May 15, 2012
Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular riskAllan D Sniderman, George Thanassoulis, Patrick R Lawler, et al.
Journal of Clinical Lipidology|July 28, 2012
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein loweringAllan Sniderman, George Thanassoulis, Patrick Couture, et al.
Trials|November 25, 2011
Five years of TrialsDouglas G Altman, Iain Hrynaszkiewicz, Curt D Furberg, et al.
Annals of Internal Medicine|July 9, 2004
ALLHAT: setting the record straightBarry R Davis, Curt D Furberg, Jackson T Wright, et al.
Clinical Chemistry and Laboratory Medicine|December 4, 2004
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary riskGöran Walldius, Ingmar Jungner, Are H Aastveit, et al.
Archives of Internal Medicine|October 13, 2006
The FDA and drug safety: a proposal for sweeping changesCurt D Furberg, Arthur A Levin, Peter A Gross, et al.
Journal of the American Heart Association|October 15, 2016
Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein CholesterolAllan D Sniderman, Shofiqul Islam, Matthew McQueen, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
Journal of Clinical Lipidology|December 16, 2014
The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular diseasePeter P Toth, George Thanassoulis, Ken Williams, et al.
American Heart Journal|August 11, 2012
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studiesDavid Madigan, Daniel W Sigelman, James W Mayer, et al.
Plos One|November 11, 2011
Suicidal behavior and depression in smoking cessation treatmentsThomas J Moore, Curt D Furberg, Joseph Glenmullen, et al.
The American Journal of Cardiology|May 15, 2012
Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular riskAllan D Sniderman, George Thanassoulis, Patrick R Lawler, et al.
Journal of Clinical Lipidology|July 28, 2012
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein loweringAllan Sniderman, George Thanassoulis, Patrick Couture, et al.
Trials|November 25, 2011
Five years of TrialsDouglas G Altman, Iain Hrynaszkiewicz, Curt D Furberg, et al.
Annals of Internal Medicine|July 9, 2004
ALLHAT: setting the record straightBarry R Davis, Curt D Furberg, Jackson T Wright, et al.
Clinical Chemistry and Laboratory Medicine|December 4, 2004
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary riskGöran Walldius, Ingmar Jungner, Are H Aastveit, et al.
Archives of Internal Medicine|October 13, 2006
The FDA and drug safety: a proposal for sweeping changesCurt D Furberg, Arthur A Levin, Peter A Gross, et al.
Journal of the American Heart Association|October 15, 2016
Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein CholesterolAllan D Sniderman, Shofiqul Islam, Matthew McQueen, et al.
Pageof 11